Variations in access to and reimbursement for continuous glucose monitoring systems for people living with Type 1 diabetes across England.

Abstract

Since the introduction of real-time continuous glucose monitoring (CGM) systems more than 15 years ago and, more recently, flash glucose monitoring (Flash-GM), clinical studies have observed reductions in HbA1c , independent of insulin delivery method, with decreasing time spent in hypoglycaemia [1] and reduction in glycaemic variability [2]. CGM can improve quality of life and reduce diabetes-related distress [3], including fear of hypoglycaemia [4,5]. Despite these benefits, CGM has yet to be fully implemented as part of the standard of care for people living with Type 1 diabetes in England, and there is considerable variation in how it is funded through local payer organizations.